Jiangsu Hengrui Pharmaceuticals Reports Increased Full-Year Profit
Jiangsu Hengrui Pharmaceuticals Co. Ltd (1276.HK) announced a significant increase in profit for its full fiscal year, exceeding the previous year’s results. The company’s bottom line reached RMB7.711 billion, equivalent to RMB1.18 per share, a rise from the RMB6.336 billion, or RMB1.00 per share, reported in the prior year. RTTNews reported the financial results on March 26, 2026.
Revenue Growth
The company also experienced a 13.0% increase in revenue, climbing to RMB31.629 billion from RMB27.984 billion the previous year. RTTNews
Company Overview
Jiangsu Hengrui Pharmaceuticals Co., Ltd., established in 1970 and headquartered in Lianyungang, China, is a research-driven pharmaceutical company. Yahoo Finance states the company focuses on the development, manufacturing, and commercialization of medicines addressing unmet clinical needs both in China and internationally. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory conditions, neuroscience, pain management, infectious diseases, hematology, ophthalmology, and autoimmune disorders. Yahoo Finance
Stock Performance (as of March 26, 2026)
As of 3:14 PM GMT+8 on March 26, 2026, Jiangsu Hengrui Pharmaceuticals (1276.HK) stock was trading at HKD 61.00, down 2.350 (-3.71%). Yahoo Finance. Key stock data includes:
- 52 Week Range: 52.500 – 95.200
- Market Cap: 426.541B
- PE Ratio (TTM): 46.21
- EPS (TTM): 1.320
- Volume: 1,608,000
Recent Developments
Recent news indicates several key developments for Jiangsu Hengrui Pharmaceuticals:
- The company published its 2025 audited annual results. CNBC
- A final 2025 dividend was proposed. CNBC
- An Annual General Meeting (AGM) is scheduled to approve dividends and a 20% share issuance mandate. CNBC
- Hengrui Pharma increased its investment in Shanghai Regenelead by RMB750 million. CNBC
- A subsidiary received NMPA approval for a new indication of an innovative HER2 breast cancer drug. CNBC
Financial Highlights (Q4 FY25)
- Revenue: RMB 8.44 billion
- Earnings: RMB 1.82 billion